Thymidine phosphorylase Inhibitors
1 drugsAbout Thymidine phosphorylase
Thymidine phosphorylase (TP), also known as platelet-derived endothelial cell growth factor (PDECGF), is an enzyme that catalyzes the reversible conversion of thymidine to thymine and 2-deoxy-alpha-D-ribose-1-phosphate. It plays a role in nucleotide metabolism and angiogenesis.
TP is a therapeutic target in oncology, where inhibiting it can disrupt nucleotide metabolism in cancer cells. Currently, there is no genetic evidence data available linking thymidine phosphorylase to specific diseases.
LONSURF is the only FDA-approved drug targeting TP, developed by TAIHO ONCOLOGY and approved in 2015. It is a small molecule used in oncology, with three indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Metastatic Gastroesophageal Junction Adenocarcinoma with only 2 trials.
Top Thymidine phosphorylase Drugs
TAIHO ONCOLOGY is the only company with an approved drug targeting thymidine phosphorylase.
High market concentration indicates potential entry barriers and limited competition.
Thymidine phosphorylase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Thymidine phosphorylase, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches.
Thymidine phosphorylase Clinical Trials 28 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 11 | 5 | 1 | 5 | 83% |
| Phase 2 | 15 | 5 | 2 | 8 | 71% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Thymidine phosphorylase Drug Approval Timeline (2015 - 2015)
LONSURF was the first and most recent drug approved in 2015, representing a 1-year span.
The single approval suggests a potentially unsaturated market with room for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 40 clinical trials targeting Thymidine phosphorylase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities